NCT00919711View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

870

Participants

Timeline

Start Date

September 1, 2009

Primary Completion Date

December 21, 2011

Study Completion Date

March 5, 2012

Conditions

Osteoporosis

Interventions

DRUG

Actonel®

Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).

DRUG

Denosumab

Denosumab 60 mg, once every 6 months, Subcutaneous

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY